LOINC
Version 2.73

80625-7Zika virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test --2nd specimenActive

Term Description

Quantitative result for Zika virus neutralizing antibodies in a convalescent phase CSF sample. Serological cross-reactivity is strong between Zika and other flaviviruses, especially Dengue virus. Therefore, positive EIA or IF assays for Zika virus IgM antibodies are presumptive only and should be confirmed by a neutralization assay, such as the plaque-reduction neutralization test (PRNT), which can discriminate between Zika virus and cross-reacting antibodies in primary flavivirus infections. Recent Zika virus infection is confirmed by stable high neutralizing antibody titers, seroconversion, or a 4x or greater increases in neutralizing antibody titer in a patient's appropriately timed acute and convalescent phase specimens.
Source: Regenstrief LOINC

Part Descriptions

LP200137-0   Zika virus
Zika virus (ZIKV) is a flavivirus transmitted primarily by the Aedes mosquito which was first identified in a sentinel monkey in the Zika forest in Uganda in 1947. Since 2014 it has spread explosively in the Americas where it has infected hundreds of thousands of people. About 80% of those infected are asymptomatic. Common symptoms include fever, headache, rash, arthralgia and conjunctivitis. Since the end of 2015, there has been an increase in ZIKV-associated cases of Guillain-Barre syndrome and a tremendous increase in cases of microcephaly in fetuses and newborns in Brazil, raising worldwide public health concern. Recent predictions are that the mosquito species A. Albopictus, which can hibernate and survive cool temperatures, will carry ZIKV to more temperate areas of North America, Australia and Southern Europe. It is still not clear whether ZIKV in humans increases viral titers enough to trigger a new cycle when an infected person is bitten by a naïve mosquito. Direct human-to-human transmission has been documented to occur perinatally, sexually (primarily through semen), through breastfeeding, blood transfusion and through occupational transmission in the laboratory setting. There are currently no specific anti-viral agents, vaccination or medical prophylaxis available. [PMID:27148186] Source: Regenstrief LOINC

LP6416-4   Neut
In LOINC, the Method "Neut" represents the virus neutralization test (VNT), also called conventional VNT, which is a specific laboratory method that is used primarily for identifying whether neutralizing antibodies for the virus of interest are present in the patient sample. The VNT involves incubating patient serum with the virus of interest, and then inoculating onto cell culture. If neutralizing antibodies are present and the virus is neutralized, the cells will not be infected. If neutralizing antibodies are not present, the virus will infect the cells in the cell culture. [PMID:32170698] This method can also be used to identify specific virus serotypes or strains, by performing separate tests in which serum is incubated with each of the specific virus serotypes or strains of interest. [PMID:169804] Source: Regenstrief LOINC

LP207365-0   Ab.Neut
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method. Source: Regenstrief LOINC

Fully-Specified Name

Component
Zika virus Ab.Neut^2nd specimen
Property
Titr
Time
Pt
System
CSF
Scale
Qn
Method
Neut

Additional Names

Short Name
ZIKV NAb sp2 Titr CSF Nt
Display Name
ZIKV neut ab spec 2 Neut test (CSF) [Titer]
Consumer Name Alpha
Zika virus neutralizing antibody specimen 2, Spinal fluid

Basic Attributes

Class
MICRO
Type
Laboratory
First Released
Version 2.56
Last Updated
Version 2.56
Order vs. Observation
Both

Member of these Groups

LG32774-8 Zika virus

Language Variants Get Info

zh-CNChinese (China)
寨卡病毒 抗体.中和^第2个标本:滴定度:时间点:脑脊液:定量型:中和试验
nl-NLDutch (Netherlands)
zikavirus As.neutraliserend^2de monster:titer:moment:liquor cerebrospinalis:kwantitatief:neutralisatietest
fr-FRFrench (France)
Zika virus Ac neutralisant 2nd prélèvement:Titre:Ponctuel:Liquide céphalorachidien:Numérique:Neutralisation
it-ITItalian (Italy)
Zika virus Ab.Neut^2° campione:Titr:Pt:LCS:Qn:Neut
es-MXSpanish (Mexico)
Ab.Neut del virus del Zika ^2da muestra:Título:Punto temporal:Fluído espinal cerebral:Cuantitativo:Prueba de neutralización
es-ESSpanish (Spain)
Virus Zika Anticuerpos antineutrófilos^2º especimen:Titulo / Factor de dilución:Punto temporal:Líquido Cefalorraquideo:Qn:Prueba de neutralización

Example Units

Unit Source
{titer} Example UCUM Units

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=80625-7